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http:WHAT THIS PAPER ADDS
In the present study the safety and the efﬁcacy of paclitaxel-eluting stents for Trans-Atlantic Inter-Society
Consensus Document on Management of Peripheral Arterial Disease (TASC) C/D femoropopliteal lesions have
been prospectively assessed. It was found that critical limb ischemia (CLI) and TASC D lesions had poorer
outcomes than claudicants and TASC C lesions.Objective: The aim was to evaluate the safety and the efﬁcacy of primary stenting with paclitaxel eluting stents
for TASC C and D femoropopliteal lesions.
Methods: Patients with TASC C/D de novo femoropopliteal lesions were treated by implanting paclitaxel eluting
stents. Patients were included in a single center registry and prospectively followed by clinical and ultrasound
evaluation. X-ray of the stented zone was systematically performed 12 months after implantation. The primary
endpoint was primary sustained clinical improvement after 12 months.
Results: A total of 45 patients (48 limbs) suffering from claudication (25 limbs) or CLI (23 limbs) were enrolled.
Lesions were either TASC C (28 limbs) or TASC D (20 limbs). The mean length of the treated segment was
252  90 mm. The mean number of stents was 2.9  1 (2e5). Mean follow up was 12.7 months. No patient was
lost to follow up. At 1 year post procedure, primary and secondary sustained clinical improvements were
56.3  7.4% and 80.1  5.9% respectively. Freedom from target lesion and target extremity revascularization
were 63.6% and 90.1%, respectively. Primary and secondary patency rates were 52.5% and 79.6%. One year
primary sustained clinical improvement rates for TASC C/D were 63.3  9.2% and 45.6  11.7%, respectively
(p ¼ .34). One year primary sustained clinical improvement rates for claudication/CLI patients were 68  9.3%
and 41.6  11.1%, respectively (p ¼ .13). The incidence of in stent re-stenosis and in stent thrombosis were 25%
and 14%, respectively. The incidence of stent fracture was 12.5% on a limb basis and 9% on a per stent basis.
Conclusions: The paclitaxel eluting stent did not achieve its goal in terms of prevention of in stent re-stenosis for
TASC C/D femoropopliteal lesions. It requires frequent re-interventions during the ﬁrst year to maintain
satisfactory clinical results.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Indications for endovascular treatment of femoropopliteal
lesions have been steadily increasing over the past decade.
Recent studies have shown that even the most challenging
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//dx.doi.org/10.1016/j.ejvs.2015.07.018up to 95%.1 An increasing number of tools are continuously
enriching the armamentarium of endovascular specialists,
and require regular updates to the available evidence.
Previous studies have established the superiority of bare
and paclitaxel eluting stents (PES) over plain balloon an-
gioplasty (POBA) for the Trans-Atlantic Inter-Society
Consensus Document II on Management of Peripheral
Arterial Disease (TASC) A/B femoropopliteal lesions.2e4
However, treatment of more challenging femoropopliteal
lesions such as TASC C/D is still unresolved. Implantation of
the latest generation of nitinol stents for femoropopliteal
long lesions has given promising results.5,6 However, in
stent re-stenosis remains a major concern after femo-
ropopliteal stent implantation, with in stent re-stenosis
occurring in up to 37%.4 In this perspective, PES
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long femoropopliteal lesions.7,8 Herein, the 1 year outcomes
of a single center prospective registry assessing the safety
and the efﬁcacy of PES in the treatment of TASC C/D
femoropopliteal lesions are reported.METHODS
Study design
STEnting Long de L’Artère fémorale superﬁcielle par Zilver-
PTX (STELLA-PTX) is a single center, prospective registry in
which patients presenting with femoropopliteal TASC C/D
de novo lesions were included between March 2011 and
April 2012. Endovascular treatment by primary stenting was
considered as a ﬁrst line treatment. This registry was
established as a pilot study to determine the safety and the
feasibility of drug eluting stents for TASC C/D femo-
ropopliteal lesions. As a result, no size calculations were
made prior to the start of the study, but all the patients
treated over a 1 year period were included. Inclusion and
exclusion criteria are summarized in the Supplementary
data. Patients had either one or two limbs treated in this
study. The protocol was approved by the local ethics com-
mittee and all patients gave their informed consent.Endovascular procedures
Endovascular procedures have already been described.6
Brieﬂy, the self expandable paclitaxel eluting stent (Zilver
PTX, Cook Medical, Bloomington, IN, USA) was the only
stent implanted (5e7 mm diameter). The maximum avail-
able length of the stent was 120 mm. Lesions were treated
with as few stents as possible. Stent diameter was chosen
to be the size of the vessel diameter, and remodeling of the
stent was achieved through the use of a balloon 1 mm
smaller than the stent. When several stents were necessary,
there was a 1 cm overlap between stent edges. Concomi-
tant procedures were performed according to the surgeon’s
preference. Groin closure was usually accomplished by
manual compression and, for day case procedures, an
arterial closure device was used (Angioseal, St Jude Medical,
Boulogne-Billancort, France).
A prophylactic dose of low molecular weight heparin was
given during hospitalization to prevent venous thrombo-
embolic events. Post-operatively, patients were prescribed
aspirin (75e160 mg/day) and clopidogrel (75 mg/day) for 6
months followed by clopidogrel alone.9 When patients were
already taking oral anticoagulants, aspirin was the only
antiplatelet agent added.Follow up
Patients were prospectively followed up on an outpatient
basis. Major adverse clinical events (MACE) and treatment
observations were intentionally sought. Follow up included
medical examination, ankle brachial index (ABI) measure-
ments and duplex scan at 1, 3, 6, 9, 12, and 18 months, and
annually thereafter. Stent fractures were assessed by biplanarX-rays at 12 months with two different projections separated
by at least 45 using the highest available magniﬁcation.
Endpoints and deﬁnitions
The primary endpoint was primary sustained clinical
improvement at 12 months.
Secondary endpoints were secondary sustained clinical
improvement, primary and secondary patency, technical
success, minor and major complications, MACE, limb
salvage, target lesion revascularization (TLR), target ex-
tremity revascularization (TER), in stent re-stenosis (ISR), in
stent thrombosis, and stent fracture. Detailed deﬁnitions of
outcomes are as follows.10
Primary sustained clinical improvement was deﬁned as a
sustained upward shift of the 1 category of the Rutherford
classiﬁcation for claudicants and by wound healing and
resolution of rest pain for patients with critical limb
ischemia (CLI), without the need for repeated TLR in sur-
viving patients. Secondary sustained clinical improvement
was deﬁned as a sustained upward shift of 1 category of
the Rutherford classiﬁcation for claudicants and by wound
healing and resolution of rest pain for patients with CLI,
including the need for repeated TLR in surviving patients.
Primary patency was deﬁned as patency without any
percutaneous or surgical re-intervention in the treated
segment or in the adjacent areas. Technical success was
deﬁned as achievement of a ﬁnal residual diameter stenosis
of <30% on the procedural completion angiogram. Minor
complications are those following the procedure (within the
ﬁrst month) and not requiring further treatment and not
extending hospital stay. Major complications refer to com-
plications occurring during the ﬁrst month following the
procedure and requiring re-intervention or delay (more than
24 hours) in patient discharge. Major cardiovascular events
included all deaths, major amputation, procedure related
serious adverse events, and device failure or malfunction.
Target lesion revascularization expresses the frequency of
the need for repeated procedures (endovascular or surgical)
due to a problem arising from the lesion (þ1 cm proximally
and distally to include edge phenomena) in surviving pa-
tients with preserved limb. Target extremity revasculariza-
tion expresses the frequency of the need for repeated
procedures (endovascular or surgical) due to a problem
arising remotely from the lesion initially treated in surviving
patients with a preserved limb. In stent re-stenosis was
assessed by duplex ultrasound and was deﬁned by re-
stenosis of more than 50% and by a peak systolic velocity
index greater than 2.4 at the target lesion. The diagnosis of
stent thrombosis was considered when a complete occlu-
sion was seen on duplex scan without any previous sign of
re-stenosis. The occurrence of stent fracture was deter-
mined by biplanar radiography at 12 months. Stent fractures
were classiﬁed according to the Jaff et al.11 classiﬁcation.
Statistical analysis
Statistical analysis results were reported prospectively on an
intention to treat basis and analyzed. Continuous variables
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count and percentages. Demographic and comorbidity data
were recorded per patient and patency data were calcu-
lated on a per limb basis. Survival rate curves for outcomes
were plotted and calculated using the KaplaneMeier
method. The timing of events (primary sustained clinical
improvement) was analyzed with a univariate Cox propor-
tional hazards model to assess the speciﬁc effect of each
predictor. For patients who died before the ﬁnal follow up
examination or for patients lost to follow up, the status of
the last follow up examination was recorded. In stent re-
stenosis at 12 months was analyzed with univariate logis-
tic models. A p value < .05 was considered statistically
signiﬁcant. Data were analyzed using the SPSS software
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patients’ characteristics and demographics
A total of 45 patients (48 limbs) were enrolled. The baseline
characteristics of the study population are described in
Table 1. During the 1 year inclusion period, 481 infra-
inguinal revascularizations (67 open surgery and 414
endovascular) were performed in the center.
Intra- and peri-operative data
Indications for intervention included 25 limbs for claudica-
tion and 23 limbs for CLI. Twenty-eight limbs were classiﬁed
as TASC C and 20 limbs as TASC D. The mean length of the
treated lesions was 252  90 mm and the total stenting
length was 291  98 mm. A mean number of 2.9  0.8 (2eTable 1. Demographic data.
All patients (n ¼ 45) IC (n ¼ 25) CLI (n
Age (mean  SD) 67  13 60  7 76 
Male sex, n 32 21 13
Smoking, n 35 23 14
Active smoking, n 18 15 4
Previous smoking, n 17 8 10
Hypertension, n 31 15 19
Hyperlipidemia, n 25 14 13
Diabetes mellitus, n 12 3 9
Type I, n 3 9 0 3
Type II, n 3 6
Obesity, n 15 8 7
Renal failure, n 8 2 6
CAD, n 16 8 10
CVD, n 7 6 1
ABI (mean  SD) 0.69  0.1 0.64  0.13 0.54
IC, n 25 e
CLI, n 23 e
Rutherford stages
3, n 25 24.2 1
4, n 8 0 6
5, n 5 0 10
6, n 5
Note. All patients: n ¼ 45, All limbs: n ¼ 48. ABI ¼ ankle brachial ind
CVD ¼ cerebrovascular disease; IC ¼ intermittent claudication; T
Management of Peripheral Arterial Disease.5) stents per limb were implanted. Concomitant endovas-
cular treatment was performed for 21 limbs. Details of these
procedures are given in Table 2. No death occurred within
the 30 days of the procedure. During the peri-operative
period, ﬁve major complications were observed: one in
stent thrombosis occurred in a patient presenting with CLI
(Rutherford 6 at baseline) that required a major amputation
after a failed attempt at ﬁbrinolysis. Four puncture site
hematomas were noted and required an extension of hos-
pital stay without re-intervention. Two minor amputations
were performed during the ﬁrst month. The average length
of hospital stay was 4.9 days (0e42). Nine limbs were
treated as day case vascular procedures. In these cases, an
arterial femoral closure device (Angioseal 6F, St Jude Med-
ical) was used. Five patients stayed longer than 20 days due
to extensive ulcers that required prolonged care.
Subgroup analysis showed that CLI patients were signif-
icantly older (p  0.001), more frequently women (p ¼ .04)
and smokers (p ¼ .004) than intermittent claudication (IC)
patients. Patients with CLI also more frequently presented
with TASC D lesions than claudicants (p ¼ .01). Treatment of
TASC D lesions required the use of more stents than TASC C
lesions (p ¼ .01).
Follow up
The mean follow up time was 12.7 months (range 12e26
months). No patient was lost to follow up. Four patients
died during the follow up period. The 1 year primary and
secondary sustained clinical improvement rates were
56.3  7.4% and 80.1  5.9%, respectively (Fig. 1A). The
mean Rutherford indices at baseline and at 12 months were¼ 23) p TASC C (n ¼ 28) TASC D (n ¼ 20) p
12 <.001 68  13 67  13 .91
.04 18 16 .24
.004 21 16 .93
.004 11 8 .93
.004 10 8 .93
.08 21 13 .45
.97 13 14 .14
8 4
.01 2 1 .62
.31 6 3 .42
.91 7 8 .35
.13 4 4 .7
.41 8 10 .15
.1 4 3 .63
 0.15 .08 0.65  0.12 0.52  0.12 .01
e e 18 8 .96
e e 10 12 .96
19 6 .01
1 7
5 3
1 4
ex; CAD ¼ coronary arterial disease; CLI ¼ critical limb ischemia;
ASC ¼ Trans-Atlantic Inter-Society Consensus Document II on
Table 2. Intra-operative data.
Variables Total IC CLI p TASC C TASC D p
Anesthesia, n
Conscious sedation 41 20 21 .67 22 19 .08
Loco-regional anesthesia 2 2 0 1 1
General anesthesia 5 3 2 5 0
ASA, n
1 2 1 1 .38 0 2 .82
2 24 14 10 16 8
3 20 10 10 13 8
4 2 0 2 0 2
Approach, n
Antegrade 16 6 10 .08 8 8 .13
Cross over 30 19 11 20 10
Pedal access 2 0 2 0 2
Stented length, mm, mean  SD 291  98 269  105 310  90 .16 251  96 341  79 .001
Number of stents, mean  SD 3  1 3  1 3  1 0.62 3  1 3  1 0.01
Number of stents, n
2 16 9 7 .73 14 2 .01
3 21 12 9 10 11
4 9 2 7 3 6
5 2 2 0 1 1
Concomitant procedures, n
Endovascular repair 21 10 11 .58 11 10 .46
CIA, EIA, IIA 6 2 4 4 2
CFA, PFA 7 2 5 3 4
BTK PTA 5 4 1 3 2
CIA, EIA and CFA, PFA 2 1 1 1 1
CFA and BTK PTA 1 1 0 0 1
Contralateral CIA, EIA 5 1 4 4 1
Contralateral CFA, PFA 2 1 1 2 0
Open repair (%) 0 0 0 0 0
ASA ¼ American Society of Anesthesiology score; BTK PTA ¼ below the knee percutaneous transluminal angioplasty; CFA ¼ common
femoral artery; CIA ¼ common iliac artery; CLI ¼ critical limb ischemia; EIA ¼ external iliac artery; IC ¼ intermittent claudication;
IIA ¼ internal iliac artery; PFA ¼ profunda femoral artery; SD ¼ standard deviation; TASC ¼ Trans-Atlantic Inter-Society Consensus
Document II on Management of Peripheral Arterial Disease.
634 J.-M. Davaine et al.4.1  1.0 and 0.8  1.3, respectively (p < .001) (Fig. 1B).
Failure to improve clinical status was observed in six limbs.
Subgroup analysis yielded a 1 year primary clinical
improvement of 63.3  9.2% for TASC C lesions and of
45.6  11.7% for TASC D lesions (p ¼ .34) (Fig. 2A). Sec-
ondary sustained clinical improvement rates were
85.1  6.9% and 72.5  10.6% for TASC C and D lesions,
respectively (p ¼ .27) (Fig. 2A). Focusing on clinical pre-
sentation, patients presenting with IC at baseline had a 1
year primary sustained clinical improvement rate of
68  9.3% compared with 41.6  11,1% for CLI patients
(p ¼ .13) (Fig. 2B). Finally, the corresponding secondary
clinical improvement rates were 91.8  5.5% and
65.9  10.7%, respectively (p ¼ .03) (Fig. 2B).
The 1 year limb salvage rate of CLI patients was 97.3%.
The mean ABI of the whole cohort increased from baseline
levels from 0.69  0.1 to 0.92  0.2 at 1 month and
0.90  0.2 at 1 year (p < .001). The number of implanted
stents, smoking status and antiplatelet regimen were not
found to inﬂuence clinical outcome at 12 month follow up.
In contrast, there was a trend towards a worse outcome
when large diameter stents (7 mm diameter vs. 5 and 6 mm
diameter) were used (p ¼ .05, HR, 7.3; CI 95% 0.97e54.35).At 1 year, primary and secondary patency rates were 52.5%
and 79.6%, respectively. During follow up, in stent throm-
bosis was noted in seven limbs and ISR in 12 limbs.
Amputation was necessary in one patient. Medical treat-
ment with a daily walking program and strict clinical sur-
veillance was chosen for two patients. The last four patients
were symptomatic. Two patients underwent a venous
femoropopliteal bypass and two patients an additional
endovascular procedure.
Of the 12 cases of ISR, eight patients presented with
symptom recurrence and four patients were asymptomatic.
In asymptomatic patients, ISR were considered as threat-
ening vessel patency in three cases. A total of 11 redo
procedures, all endovascular, were performed. Only two
patients were considered not improved at the 12 month
follow up. Accordingly, TLR and TER free cumulative survival
rates were 64% and 90%, respectively. All patients received
at least one antiplatelet agent for the ﬁrst 12 months and
50% of them were on both aspirin and clopidogrel for the
ﬁrst 6 months.
Complete X-ray follow up was obtained for 29 treated
limbs. Eighty-nine stents were analyzed and eight fractures
(4 type II and 4 type IV) were noted.
Figure 1. Clinical outcomes. (A) Primary and secondary sustained clinical improvement. (B) Rutherford stages at baseline and 1 year.
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In this prospective registry, it has been shown that PES did
not achieve their objective in terms of prevention of in stent
re-stenosis for long femoropopliteal TASC C/D lesions.
Although not recorded in this study, technical success was
close to 90% as reported previouly.12,13 Numerous re-
interventions were required, however, to treat ISR and to
maintain clinical improvement despite paclitaxel release.
Moreover, there was a trend toward worse clinical
improvement and patency in CLI patients and TASC D
femoropopliteal lesions.Paclitaxel eluting stents and TASC C/D femoropopliteal
lesions
Few studies evaluating PES for TASC C/D femoropopliteal
lesions are available.7,8,14
The largest registry using the Zilver-PTX PES included 135
limbs and was published in 2013.7 One hundred and thirty
ﬁve limbs were included. Of note, no clinical data (Ruth-
erford stage and TASC C/D status) were provided. More
recently, Zeller et al.14 have published a comparison be-
tween PES (Zilver-PTX) and paclitaxel eluting balloons
(IN.PACT balloons, Medtronic Vascular, Roncadelle, Italy)
based on the treatment of 239 patients. The 97 PES patientshad lesions averaging 195.0  64.5 mm (range 100e
350 mm) in length with only 7.2% of the patients presenting
with CLI. The main limitation of this study was the hetero-
geneity of the lesions, which were very heterogeneous since
de novo (55.7%), re-stenotic (44.3%) and short lesions
<10 cm were included. In 2014, Leopardi et al.8 published
an evaluation of the effectiveness of Zilver-PTX for long
femoropopliteal lesions. Again, the main drawback of this
cohort was the heterogeneity of the treated lesions, with
only 47.8% de novo lesions, and a short follow up of 5.3
months.4,15
Patency and re-intervention
In STELLA PTX, primary and secondary patency rates at 1
year were 52.5%  7.6 and 79.6%  6.1%. The differences
observed here contrast with the results of the Zilver PTX
randomized controlled trial (1 year primary patency rate of
83.1% for PES) and highlights the speciﬁc feature of TASC C/
D lesions.2 These patency results are also much lower than
those of the Zilver PTX single arm registry (77.6% of primary
patency).7 In contrast, the 79.6% secondary patency is
within the 77.6e83.1% range observed in the two other
studies. When comparing a drug eluting balloon and PES,
Zeller et al.14 reported a binary re-stenosis rate of 30.4% in
the PES cohort and the clinically driven TLR rate was 19.0%.
Figure 2. Primary and secondary sustained clinical improvement according the TASC II classiﬁcation and the clinical presentation. (A)
According the TASC II classiﬁcation. (B) According to the clinical presentation. CLI ¼ critical limb ischemia; IC ¼ intermittent claudication;
TASC ¼ the Trans-Atlantic Inter-Society Consensus Document II on Management of Peripheral Arterial Disease.
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stenosis in the PES group, which is similar to the ﬁndings
here (25% of in stent re-stenosis at 1 year). The TLR rate was
lower in the Zeller study (19%) than here (36%). It may
result from the fact that in STELLA-PTX, re-interventions
were not just required for the recurrence of symptoms, but
also in asymptomatic cases threatening re-stenosis. The
occurrence of in stent re-stenosis or in stent thrombosis
was not found to be related to the prescription of one or
two antiplatelet agents (data not shown).Clinical improvement
Despite a high rate of re-interventions, clinical improvement
was achieved. Indeed, at baseline, 23 limbs presented with
CLI versus one 1 year later, and the 1 year limb salvage rate
of CLI patients was 97.3%. Some authors have evoked the
negative impact of failed endovascular treatment on sub-
sequent bypasses,16 which has not been conﬁrmed by
recent reports.17,18 On the other hand, failure of bypass as a
ﬁrst line treatment has a poor prognosis too. Indeed, the 2
year limb salvage rate for occluded grafts performed for rest
pain and tissue loss are 55% and 34%, respectively.19Stent fractures
Eight stent fractures at 1 year (12.5% on a limb basis and 9%
on a stent basis) were reported, compared with 2.1% in the
single arm Zilver PTX study (subgroup TASC C/D).7 Previous
reports have suggested a positive association between the
number of stents implanted and stent fractures due to stent
overlap. The results here challenge this suggestion. Indeed,
the maximum stent length available here was 120 mm
compared with 80 mm in the Zilver PTX TASC C/D subgroup,
and the mean number of corresponding stents was 2.9 and
3.4, respectively. A more likely explanation for the higher
stent fracture rate observed here could be related to the
high proportion of TASC D with popliteal artery involve-
ment. Indeed, seven out of the eight stent fractures
occurred in the femoropopliteal transition zone, suspected
to be critical in terms of material fatigue and stress.20
Study limitations
The main limitations of this study were the absence of a
control group and the relatively small patient sample size.
The inclusion of patients in this study was inﬂuenced by
certain criteria such as the ability to cross the target lesion
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lesions. Consequently, the conclusions of this study do not
apply to these lesion subgroups and, in particular, to highly
calciﬁed lesions, which are predictive of technical failure.6 In
43% of the cases, concomitant endovascular procedures
were performed to improve outﬂow or inﬂow. These pro-
cedures had an impact on the outcome of the femoral
stenting, and this constitutes a potential bias in the assess-
ment of clinical improvement. A subjective clinical scale to
evaluate clinical status was used, and a quality of life ques-
tionnaire was not used. Moreover, no objective measure of a
patient mobility, such as the treadmill test, was included.
To conclude, this registry conﬁrms that endovascular
repair may be considered as a ﬁrst line of treatment for
TASC C/D femoropopliteal lesions. The PES did not achieve
its goal in terms of prevention of in stent re-stenosis for
TASC C/D femoropopliteal lesions. It requires frequent re-
interventions during the ﬁrst year to maintain satisfactory
clinical results. Besides, it appears that CLI and TASC D le-
sions had poorer outcomes than claudicants and TASC C
lesions, respectively. Endovascular treatment modalities for
long femoropopliteal lesions should be evaluated further.
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